SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
SciSparc (Nasdaq: SPRC) announced on September 16, 2025 a board resolution to launch an initiative to develop quantum-powered 3D protein modeling for drug discovery, with a focus on neurological and rare diseases.
The program will form a dedicated research team, create a wholly owned Israeli subsidiary, collaborate with experts in quantum computing and structural biology, refine quantum algorithms for protein folding and protein-ligand interactions, and seek new intellectual property.
SciSparc (Nasdaq: SPRC) and Clearmind (Nasdaq: CMND) announced the publication of a U.S. patent application on Oct 20, 2025 covering a combination therapy of MEAI (5-methoxy-2-aminoindane) and N‑Acylethanolamines such as Palmitoylethanolamide (PEA) to address binge behavior disorders.
The patent application cites multiple binge behaviors including excessive alcohol use, eating disorders, tobacco use, compulsive shopping, and problematic sexual conduct. The filing describes a therapeutic rationale: MEAI to reduce impulsivity and reward-seeking and PEA for anti-inflammatory and neuroprotective support. The collaboration targets conditions including alcohol use disorder, cocaine addiction, obesity, and depression, and cites preclinical data supporting potential efficacy in reducing binge episodes while preserving natural reward pathways.
SciSparc (Nasdaq: SPRC) entered a definitive asset-and-share purchase agreement dated October 9, 2025, to transfer its advanced clinical-stage pharmaceutical portfolio and a ~51% stake in SciSparc Nutraceuticals into Miza III Ventures (TSXV: MIZA.P).
The agreement values the Target Assets at approximately US$11.6M and Miza enterprise value at approximately US$3.3M. SciSparc will receive 63,300,000 Miza common shares plus up to 48,000,000 contingent rights, yielding an expected post-close controlling interest of ~75%–84%. TSXV granted conditional approval; closing is anticipated on or about Oct 22, 2025. SciSparc may commit up to CAD1.0M via a 2-year convertible note at 7% and will receive 4,000,000 warrants exercisable at CAD0.25 for five years.
SciSparc (Nasdaq: SPRC) announced a framework agreement dated October 6, 2025 with AutoMax Motors and SciSparc Merger Sub to mutually terminate the April 10, 2024 Merger Agreement, effective immediately, the PR states.
Under the framework, AutoMax will: (1) repay a $4.25 million loan plus 9% per annum interest compounded annually in a single lump sum on January 1, 2028; and (2) repay a $2.0 million loan via $60,000 monthly installments beginning November 20, 2025 with 8% per annum interest compounded annually to each payment date. The PR also states accrued interest of $114,523 (from Feb 24, 2025 to Nov 20, 2025) will be paid at the outset.
SciSparc Ltd. (Nasdaq: SPRC) announced that N2OFF (NASDAQ: NITO) shareholders have approved the acquisition of SciSparc's majority-owned subsidiary MitoCareX Bio Ltd., a drug discovery company focused on developing therapies for resistant cancers. The deal structure includes a $700,000 cash payment for 6,622 MitoCareX shares and an equity exchange giving sellers 40% of N2OFF's fully diluted capital stock.
The transaction includes significant milestone-based incentives, with sellers entitled to 30% of N2OFF's financing proceeds (capped at $1.6M) over five years and potential additional stock issuances of up to 25% of N2OFF's common stock. N2OFF has committed to a $1M initial investment to support MitoCareX's operations post-closing. The deal is expected to close in early October 2025.
SciSparc (NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced its board's resolution to launch a groundbreaking initiative leveraging quantum computing for 3D protein modeling in drug discovery. The initiative aims to revolutionize structural biology and personalized medicine through enhanced protein structure prediction and interaction analysis.
The company plans to establish a dedicated research team and form collaborations with quantum computing and structural biology experts. The program will focus on developing quantum-enabled tools for protein folding prediction, protein-ligand interaction modeling, and accelerated drug discovery, particularly for neurological and rare diseases. SciSparc will incorporate a new Israeli subsidiary to operate this initiative.
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced that shareholders of both SciSparc and AutoMax Motors Ltd. have approved their proposed merger. The strategic reverse merger will result in SciSparc acquiring 100% of AutoMax's share capital, with SciSparc shareholders retaining 50.01% ownership of the combined company.
AutoMax, a leading parallel vehicle importer in Israel, specializes in importing and distributing electric vehicles from Anhui Jianghuai Automobile Group. SciSparc has already provided financial support to AutoMax through a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025. The merger's completion remains subject to Israeli court approval.
SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, announced that shareholders have approved its merger with AutoMax Motors, a leading parallel vehicle importer in Israel. The strategic reverse merger will result in SciSparc acquiring 100% of AutoMax's share capital, with SciSparc shareholders retaining 50.01% of the combined company.
The merger represents a significant pivot from SciSparc's pharmaceutical focus to include automotive operations, particularly in electric vehicle distribution. SciSparc has already invested in AutoMax through a $4.25 million bridge loan in 2024 and an additional $2 million loan in February 2025. The deal's closing remains subject to AutoMax shareholder approval and Israeli court approval.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have achieved a significant milestone with the publication of an international patent application for their novel combination therapy. The therapy combines Clearmind's MEAI with SciSparc's Palmitoylethanolamide (PEA) to target metabolic syndrome and obesity.
The patent application, published under the European Patent Office, represents one of 13 patent families filed across multiple jurisdictions including the US, Europe, and China. The collaboration aims to address conditions affecting up to one-third of U.S. adults, combining PEA's anti-inflammatory properties with MEAI's pharmacological profile to treat metabolic disorders, mental health conditions, and addictions.
SciSparc (Nasdaq: SPRC), a clinical-stage pharmaceutical company, reported significant progress in its proposed reverse merger with AutoMax Motors, Israel's exclusive importer of JAC electric vehicles. The SEC has declared effective the Form F-4 registration statement for the merger on July 21, 2025.
The merger agreement, initially announced in April 2024, will result in SciSparc acquiring 100% of AutoMax's share capital. Special shareholder meetings are scheduled for August 25, 2025 (SciSparc) and August 28, 2025 (AutoMax) to vote on the merger approval. The transaction remains subject to shareholder approvals from both companies and Israeli court approval.